FY2024 Earnings Forecast for ARTV Issued By HC Wainwright

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Artiva Biotherapeutics in a report issued on Monday, December 30th. HC Wainwright analyst E. White expects that the company will earn ($6.00) per share for the year. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.68) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.76) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($0.78) EPS and FY2027 earnings at ($0.92) EPS.

Separately, Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artiva Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $21.00.

Artiva Biotherapeutics Stock Down 1.1 %

Shares of NASDAQ ARTV opened at $9.97 on Wednesday. The company’s 50 day simple moving average is $11.36. Artiva Biotherapeutics has a 12 month low of $9.68 and a 12 month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $152,234,000. Franklin Resources Inc. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $7,435,000. Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth about $4,774,000. Samsara BioCapital LLC purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $4,506,000. Finally, Wellington Management Group LLP acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.